Synthetic data is moving from “nice-to-have” augmentation to a governed, lifecycle-wide capability. New review, policy, and ethics coverage point to the same operational reality: teams need measurable utility, privacy risk controls, and clear rules for when synthetic should (and should not) replace real data.
A Scoping Review of Synthetic Data Generation by Language Models for Biomedical Applications
An arXiv scoping review surveys 59 studies (2020–2025) on using large language models to generate synthetic biomedical and clinical data. It finds prompt-based generation is the dominant approach (74.6% of studies), with applications spanning EHR-style data synthesis and synthetic radiology reports used in cancer detection workflows. The paper positions LLM-based synthesis as a response to data scarcity, privacy constraints, and fairness gaps in clinical research.
- For ML leads: prompt-based generation’s prevalence suggests benchmarking should compare prompts, not just models, and track drift across model versions.
- For compliance: healthcare use cases heighten the need to document privacy assumptions and downstream use limits (training vs. evaluation vs. sharing).
- For founders: radiology-report and EHR-like synthesis are becoming table stakes—differentiation shifts to governance, validation, and integration.
Synthetic Data: The New Data Frontier
The World Economic Forum publishes a strategic brief framing synthetic data as a cross-sector tool to address scarcity, privacy restrictions, and representativeness issues. It offers governance recommendations and highlights use cases in healthcare, e-commerce, and child behavior modeling. The report also calls out hybrid approaches that combine synthetic and organic data to reduce risks like model collapse and to support equity goals.
- Policy direction is converging on “synthetic + real” as the default, implying procurement and audits will ask for mixing strategies and rationale.
- Data teams should plan for representativeness checks as a first-class deliverable, not an afterthought.
Synthetic data created by generative AI poses ethical challenges
NIEHS bioethicist David Resnik outlines ethical challenges with GenAI-created synthetic data, noting synthetic data’s long history but emphasizing how systems like ChatGPT accelerate scale and accessibility. The piece frames synthetic data governance as a public-interest issue for research and clinical settings, where misuse or overconfidence can propagate harm. It reinforces that “synthetic” does not automatically mean “safe,” especially when outputs can encode sensitive patterns or bias.
- Ethics scrutiny is shifting from “did you de-identify?” to “what harms can this synthetic dataset still enable?”
- Teams should maintain clear documentation of intended use, prohibited use, and validation limits to avoid overclaiming safety.
- Expect more stakeholder review (IRBs, ethics boards, regulators) as synthetic data becomes a default sharing mechanism.
Synthetic Data for Artificial Intelligence and Machine Learning
SPIE’s Defense + Commercial Sensing 2025 proceedings volume compiles 13 sessions and 33 papers on synthetic data for AI/ML, reflecting current research and industry practice in high-stakes domains. As a peer-reviewed venue, it signals continued technical maturation and experimentation across defense and commercial sensing applications.
- Peer-reviewed proceedings can become “evidence” in vendor evaluation—useful for due diligence in regulated or safety-critical deployments.
- Defense/commercial crossover tends to accelerate tooling standardization (simulation pipelines, labeling practices, and validation norms).
Examining the Expanding Role of Synthetic Data Throughout the AI Lifecycle
An ACM study draws on 29 interviews with AI practitioners and responsible AI experts to map how synthetic data is used from training through deployment. The qualitative angle emphasizes operational reality: adoption decisions are shaped by governance gaps, organizational incentives, and the need to reconcile privacy goals with model performance.
- Lifecycle use implies you need controls at multiple points: generation, evaluation, monitoring, and re-generation when distributions shift.
- Responsible AI teams can use practitioner evidence to justify budget for validation, documentation, and ongoing risk assessment.